Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRN04894 in Congenital Adrenal Hyperplasia
2023-503488-40-00Phase 2Completed
- Sponsor
- Crinetics Pharmaceuticals
- Start
- Nov 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of atumelnant in 21-hydroxylase deficiency (21-OHD), sponsored by Crinetics Pharmaceuticals. Primary endpoints: Incidence of treatment-emergent adverse events (TEAEs) and Change from baseline in morning serum androstenedione (A4) at Week 12. Started Nov 2023; status: completed.
02
Drugs
atumelnant
03
Conditions
21-hydroxylase deficiency (21-OHD)
Beyond the preview
Go deeper on 2023-503488-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503488-40-00.